CANADABIS CAPITAL INC(TSX-V:CANB) stock Fundamental Analysis

Fundamental Rating

Overall CANB gets a fundamental rating of 3 out of 10. We evaluated CANB against 35 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of CANB while its profitability can be described as average. CANB does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CANB has reported negative net income.

CANB had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: CANB reported negative net income in multiple years.

CANB had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of 0.82%, CANB belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.

CANB has a Return On Equity of 2.58%. This is amongst the best in the industry. CANB outperforms 83.78% of its industry peers.

The Return On Invested Capital of CANB (2.13%) is better than 81.08% of its industry peers.

The Average Return On Invested Capital over the past 3 years for CANB is significantly above the industry average of 6.37%.

The last Return On Invested Capital (2.13%) for CANB is well below the 3 year average (13.87%), which needs to be investigated, but indicates that CANB had better years and this may not be a problem.

		Industry Rank	Sector Rank
ROA	0.82%
ROE	2.58%
ROIC	2.13%

ROA(3y)8.58%

ROA(5y)-7.49%

ROE(3y)30.91%

ROE(5y)-44.74%

ROIC(3y)13.87%

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 1.24%, CANB belongs to the best of the industry, outperforming 81.08% of the companies in the same industry.

Looking at the Operating Margin, with a value of 2.54%, CANB is in the better half of the industry, outperforming 75.68% of the companies in the same industry.

CANB has a better Gross Margin (48.81%) than 70.27% of its industry peers.

CANB's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	2.54%
PM (TTM)	1.24%
GM	48.81%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y10.23%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CANB is still creating some value.

Compared to 1 year ago, CANB has about the same amount of shares outstanding.

The number of shares outstanding for CANB has been increased compared to 5 years ago.

Compared to 1 year ago, CANB has an improved debt to assets ratio.

2.2 Solvency

CANB has an Altman-Z score of 0.53. This is a bad value and indicates that CANB is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.53, CANB is in the better half of the industry, outperforming 67.57% of the companies in the same industry.

A Debt/Equity ratio of 0.77 indicates that CANB is somewhat dependend on debt financing.

CANB has a Debt to Equity ratio of 0.77. This is in the lower half of the industry: CANB underperforms 64.86% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.77
Debt/FCF	N/A
Altman-Z	0.53

ROIC/WACC0.26

WACC8.32%

2.3 Liquidity

A Current Ratio of 1.14 indicates that CANB should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.14, CANB is doing worse than 67.57% of the companies in the same industry.

A Quick Ratio of 0.33 indicates that CANB may have some problems paying its short term obligations.

The Quick ratio of CANB (0.33) is worse than 81.08% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.14
Quick Ratio	0.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CANB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -95.37%.

Looking at the last year, CANB shows a very negative growth in Revenue. The Revenue has decreased by -24.19% in the last year.

The Revenue has been growing by 37.77% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-95.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-54.9%

Revenue 1Y (TTM)-24.19%

Revenue growth 3Y37.77%

Revenue growth 5YN/A

Sales Q2Q%-11.44%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

CANB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CANB is cheaper than 72.97% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	11.34

4.3 Compensation for Growth

CANB has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CANB!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CANADABIS CAPITAL INC

TSX-V:CANB (3/7/2025, 7:00:00 PM)

0.075

+0.01 (+15.38%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)N/A N/A

Earnings (Next)03-27 2025-03-27

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners53.52%

Ins Owner ChangeN/A

Market Cap10.35M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.6
P/FCF	N/A
P/OCF	N/A
P/B	1.24
P/tB	1.24
EV/EBITDA	11.34

EPS(TTM)0

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0.13

BVpS0.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	0.82%
ROE	2.58%
ROCE	3.48%
ROIC	2.13%
ROICexc	2.25%
ROICexgc	2.25%
OM	2.54%
PM (TTM)	1.24%
GM	48.81%
FCFM	N/A

ROA(3y)8.58%

ROA(5y)-7.49%

ROE(3y)30.91%

ROE(5y)-44.74%

ROIC(3y)13.87%

ROIC(5y)N/A

ROICexc(3y)16.34%

ROICexc(5y)N/A

ROICexgc(3y)16.34%

ROICexgc(5y)N/A

ROCE(3y)24.27%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y10.23%

GM growth 5YN/A

F-Score2

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	0.77
Debt/FCF	N/A
Debt/EBITDA	4.78
Cap/Depr	40.84%
Cap/Sales	2.13%
Interest Coverage	0.97
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.14
Quick Ratio	0.33
Altman-Z	0.53

F-Score2

WACC8.32%

ROIC/WACC0.26

Cap/Depr(3y)74.66%

Cap/Depr(5y)403.75%

Cap/Sales(3y)2.7%

Cap/Sales(5y)24.48%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-95.37%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-54.9%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-24.19%

Revenue growth 3Y37.77%

Revenue growth 5YN/A

Sales Q2Q%-11.44%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-90.82%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-210.65%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-179.9%

OCF growth 3YN/A

OCF growth 5YN/A

CANADABIS CAPITAL INC (CANB.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens